12/4
06:44 am
dtil
Precision Biosciences: Still Swinging And Finally Drawing Blood [Seeking Alpha]
Low
Report
Precision Biosciences: Still Swinging And Finally Drawing Blood [Seeking Alpha]
11/26
02:14 pm
dtil
Precision BioSciences (NASDAQ:DTIL) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Precision BioSciences (NASDAQ:DTIL) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
07:13 am
dtil
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 [Yahoo! Finance]
Medium
Report
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 [Yahoo! Finance]
11/19
07:01 am
dtil
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025
Medium
Report
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025
11/11
04:13 pm
dtil
Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript [Seeking Alpha]
Neutral
Report
Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript [Seeking Alpha]
11/10
06:12 pm
dtil
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants
High
Report
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants
11/10
05:39 pm
dtil
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts [Yahoo! Finance]
Low
Report
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts [Yahoo! Finance]
11/10
05:21 pm
dtil
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts
Low
Report
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts
11/3
07:01 am
dtil
Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update
10/31
08:08 pm
dtil
Precision BioSciences, Inc.'s (NASDAQ:DTIL) one-year returns climbed after last week's 24% gain, institutional investors must be happy [Yahoo! Finance]
High
Report
Precision BioSciences, Inc.'s (NASDAQ:DTIL) one-year returns climbed after last week's 24% gain, institutional investors must be happy [Yahoo! Finance]
10/31
07:01 am
dtil
Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025
Low
Report
Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025
10/14
07:01 am
dtil
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025
Medium
Report
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025
10/9
07:15 am
dtil
Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases [Yahoo! Finance]
Low
Report
Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases [Yahoo! Finance]
10/9
07:01 am
dtil
Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases
Low
Report
Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases
10/7
07:33 am
dtil
Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial [Yahoo! Finance]
Low
Report
Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial [Yahoo! Finance]
10/7
07:01 am
dtil
Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial
Low
Report
Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial
10/2
08:00 am
dtil
iECURE to Present OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at the European Society of Gene & Cell Therapy Annual Congress and the American Society of Human Genetics Annual Meeting
Low
Report
iECURE to Present OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at the European Society of Gene & Cell Therapy Annual Congress and the American Society of Human Genetics Annual Meeting
9/30
07:45 am
dtil
Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society [Yahoo! Finance]
Medium
Report
Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society [Yahoo! Finance]
9/30
07:01 am
dtil
Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society
Medium
Report
Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society
9/12
07:19 am
dtil
Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium [Yahoo! Finance]
Low
Report
Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium [Yahoo! Finance]
9/12
07:01 am
dtil
Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium
High
Report
Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium
9/8
07:01 am
dtil
Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status
Low
Report
Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status